Previous Close | 0.1500 |
Open | 0.1500 |
Bid | 0.1350 x N/A |
Ask | 0.1500 x N/A |
Day's Range | 0.1350 - 0.1500 |
52 Week Range | 0.0900 - 0.1800 |
Volume | |
Avg. Volume | 0 |
Market Cap | 4.93M |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Principal Technologies Inc. (the "Company") (TSXV: PTEC) (FSE: J07), is pleased to announce that on March 8, 2024, it entered into a binding commitment letter with the effect that the GreenIslands Opportunities Fund (the "Lender") will provide a secured loan in the principal amount of €8,000,000 (the "Loan") to provide acquisition financing with respect to the cash portion of the purchase price for Vivostat A/S ("Vivostat"), as further outlined in its news release dated February 6, 2024, and for
Principal Technologies Inc. (the "Company" or "Principal") (TSXV: PTEC) (FSE: J07), is pleased to announce that as at February 6, 2024, it entered into an arm's length binding Share Purchase Agreement ("SPA") to acquire (the "Acquisition") 100% of the equity interests of Vivostat, a 23-year-old Danish company which uses a unique autologous fibrin sealant solution for post-surgical use.
Principal Technologies Inc. (the "Company") (TSXV: PTEC), is pleased to announce the closing of the third and final tranche ("Tranche 3") of its previously announced non-brokered private placement (the "Offering"). The Company issued an additional 833,333 common shares (the "Shares") at $0.15 per Share for gross proceeds of $124,999.95, bringing the total offering to 9,993,166 Shares for aggregate gross proceeds of $1,498,974.95 when combined with the two previous closings, subject to final appr